Page 5 - Dme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dme Today - Breaking & Trending Today

Key Clinical Findings From the PULSAR and PHOTON Trials for High-Dose Aflibercept

M. Ali Khan, MD, FACS, FASRS, reviews the PULSAR and PHOTON clinical trials of high-dose aflibercept for treatment of nAMD and DME. ....

M Ali Khan , Bali Khan , Extended Durability ,

Safety of New Therapies in nAMD and DME

Retina specialists highlight the safety data of both faricimab and high-dose aflibercept for use in treating nAMD and DME. ....

M Ali Khan , Bali Khan , Safety Signals ,

Use of Faricimab in Clinical Practice in nAMD and DME

Drs Rishi P. Singh and M. Ali Khan review the real-world experience of using faricimab to treat nAMD and DME, as well as its durability compared to clinical trials. ....

M Ali Khan , Bali Khan , Extended Durability ,

Extending Treatment Intervals in nAMD and DME

Rishi P. Singh, MD, and M. Ali Khan, MD, FACS, FASRS, discuss the need for extending treatment durability for neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME], as well as approaches to applying treat-and-extend strategies. ....

United States , Granite Bay , Cleveland Clinic , Bali Khan , M Ali Khan , Treatment Intervals With Durable Therapies , Diabetic Macular Edema , Cleveland Clinic Martin Hospital , Extending Treatment Intervals , Durable Treatment , Fluid On Oct ,

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints with robust statistical significanceOn track to commence Stage 2 of the DIAMOND program with two parallel global Phase 3 trialsIf approved, OCS-01 has the potential to become the first topical eye drop for the treatment of DME ZUG, Switzerland and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) Oculis Ho ....

France General , United States , Noord Holland , Sylvia Cheung , Corey Davis , Ramin Tadayoni , Adolphe De Rothschild Foundation , Oculis Holding Ag Nasdaq , Department Head At Lariboisi , Professor Ramin Tadayoni , Best Corrected Visual Acuity , Paris Cit , Department Head , Saint Louis , Oculi Scientific Advisory Board , Chief Executive Officer , Diabetic Macular Edema , Professor Ramin Tadayoni , Rofessor Tadayoni , Opical Eye Drop , Oculis Holding Ag , Iopharmaceutical Company , Topical Treatment ,